The estimated Net Worth of Martin Shkreli is at least $14.9 Million dollars as of 14 November 2014. Martin Shkreli owns over 1,172,000 units of Retrophin stock worth over $123,562 and over the last 12 years Martin sold RTRX stock worth over $14,790,416.
Martin has made over 34 trades of the Retrophin stock since 2012, according to the Form 4 filled with the SEC. Most recently Martin sold 1,172,000 units of RTRX stock worth $10,360,480 on 14 November 2014.
The largest trade Martin's ever made was selling 1,172,000 units of Retrophin stock on 14 November 2014 worth over $10,360,480. On average, Martin trades about 63,484 units every 19 days since 2012. As of 14 November 2014 Martin still owns at least 1,765,168 units of Retrophin stock.
You can see the complete history of Martin Shkreli stock trades at the bottom of the page.
Martin's mailing address filed with the SEC is 777 THIRD AVENUE, 22ND FLOOR, , NEW YORK, NY, 10017.
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer, and Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Retrophin executives and other stock owners filed with the SEC include: